Triagonist Landscape 2026

The shape of the landscape

"Next-gen obesity peptide" is a marketing label — the underlying mechanisms are quite different. Three of the four compounds on this page are injected peptides; one is an oral small molecule. Two are single-molecule multi-receptor agonists; one is a co-formulation. Only reta is a true GLP-1 / GIP / glucagon triagonist molecule.

The receptor families that matter:

• GLP-1 — incretin; suppresses appetite, slows gastric emptying, augments insulin secretion
• GIP — incretin; complements GLP-1 effects, may improve GI tolerability of co-agonists
• Glucagon — increases energy expenditure and hepatic fat clearance
• Amylin — adjacent to GLP-1; reduces appetite and slows gastric emptying through a separate pathway

At a glance

Reta — the triagonist anchor

Reta — retatrutide (LY-3437943) — is the only molecule on this page that hits all three receptors that drive the obesity-peptide story: GLP-1 (appetite), GIP (incretin amplification), and glucagon (energy expenditure). The TRIUMPH-4 readout in April 2026 returned ~28.7% mean weight loss at 12mg/wk over 72 weeks — the largest published number in the obesity-peptide class to date.

Trade-off: glucagon agonism comes with steeper GI tolerability costs at higher doses. The dose ladder is slow (1 / 2 / 4 / 8 / 12 mg with ~4 weeks per step) and the post-approval safety database doesn't exist yet because retatrutide is still in Phase 3.

For verifiable reta (retatrutide) research material in 2026, the COA archive lists the current pen and vial batches with Janoshik task IDs: remyresearch.com/coa/.

Cagrisema — the amylin combo play

Cagrisema is not a triagonist molecule; it's a fixed-dose co-formulation of cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) developed by Novo Nordisk. The bet is that amylin adds to GLP-1's appetite-suppression through a different receptor pathway, giving incremental weight loss without escalating GI side effects the way pure GLP-1 dose-escalation does.

REDEFINE-1 readouts have come in around 22% weight loss — meaningfully larger than semaglutide alone (~15%) but smaller than reta. The "two molecules in one pen" structure is novel and may differentiate on tolerability rather than headline percentage.

Survodutide — the dual GLP-1 / glucagon

Survodutide (BI 456906) is a dual GLP-1 / glucagon agonist from Boehringer Ingelheim and Zealand Pharma. Skips the GIP receptor that tirzepatide and reta both hit. The GLP-1 + glucagon combination is the same pair reta uses minus GIP — testing whether GIP is necessary or whether GLP-1 + glucagon alone is enough.

Phase 2 readouts in obesity hit ~19% at 4.8mg/wk over 46 weeks. Phase 3 in MASH (metabolic dysfunction-associated steatohepatitis) is also progressing — the glucagon component improves hepatic fat clearance, which is a separate clinical use case from weight loss.

Orforglipron — the oral outlier

Orforglipron is the structural odd one out: an oral small molecule, not an injected peptide. It binds GLP-1 receptor only — no GIP, no glucagon, no amylin. Headline weight loss is smaller (~14% in ATTAIN Phase 3) but the oral route changes the cost structure, distribution, and patient experience entirely.

For research purposes, orforglipron sits in a different supply chain than the injectable peptides on this page; the small-molecule manufacture is closer to traditional small-molecule pharma than peptide synthesis.

Where this leaves the field

Reta leads on headline weight-loss percentages and is the only true triagonist. Cagrisema brings a different combinatorial bet (amylin) at slightly lower percentages. Survodutide tests whether GIP is necessary at all. Orforglipron tests whether GLP-1 alone, taken orally, is enough for a meaningful share of the market. All four will publish more data in 2026; the picture will sharpen.

For research-context comparison of reta specifically against tirzepatide (the current GLP-1 / GIP standard), see Reta vs Tirzepatide.